We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Antidiabetic Properties of Rose Hip

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01316016
First Posted: March 16, 2011
Last Update Posted: March 16, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Lund University
  Purpose
The purpose of this study is to determine whether daily intake of a drink containing rose hip powder reduces risk markers of type diabetes and cardiovascular disease.

Condition Intervention
Obesity Dietary Supplement: Rose hip

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effects of Rose Hip Intake on Risk Markers of Type 2 Diabetes and Cardiovascular Disease: a Randomized Double-blind Cross-over Investigation in Obese Persons

Further study details as provided by Lund University:

Enrollment: 31
Study Start Date: April 2009
Study Completion Date: January 2011
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Rose hip Dietary Supplement: Rose hip
40 g of rose hip powder daily for 6 weeks.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • BMI > 30
  • willingness to participate in the study
  • willingness to comply with the daily intake of drinks and the recommended energy intake during the course of the study

Exclusion Criteria:

  • diabetes
  • previous or ongoing insulin treatment
  • abnormal thyroid status
  • abnormal liver status
  • abnormal kidney status
  • known gastrointestinal disorder
  • pregnancy
  • suspected allergy to ingredients of the drinks
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01316016


Locations
Sweden
Endocrinology Clinic, Lund University Hospital
Lund, Sweden, SE-22185
Sponsors and Collaborators
Lund University
Investigators
Study Chair: Per Katzman, MD/PhD Lund University
  More Information

Additional Information:
Publications:
Responsible Party: Cecilia Holm, Lund University
ClinicalTrials.gov Identifier: NCT01316016     History of Changes
Other Study ID Numbers: LUAFC002
First Submitted: March 15, 2011
First Posted: March 16, 2011
Last Update Posted: March 16, 2011
Last Verified: February 2011

Keywords provided by Lund University:
obesity
glucose intolerance
cholesterol
blood pressure